21 January 2023: Articles
Complement-Mediated Thrombotic Microangiopathy with 10 Years of Stable Renal Function After a Year-Long Treatment with Eculizumab with Coincidental Polycystic Kidney Disease
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease
Mehul P. Dixit A* , Lucy Woolverton A , Sabahat Afshan EDOI: 10.12659/AJCR.938367
Am J Case Rep 2023; 24:e938367
Figure 1. Patient’s laboratory values during the first year of illness. The graphs demonstrate recovery from cTMA, as indicated by improved kidney function, increased hemoglobin, and restoration of LDH back to within the normal range.cTMA – complement-mediated thrombotic microangiopathy; LDH – lactate dehydrogenase; Day 0 – nadir values at onset of the disease; Start Ecu – start of Eculizumab therapy; End HD – end of hemodialysis treatment: End Ecu – end of eculizumab treatment.